Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent
PLOS One · 2025
DOI: 10.1371/journal.pone.0323931 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Peerut Chienwichai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand. Hauptthemen laut MEDLINE: Rabies, Antiviral Agents, Rabies virus, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chulabhorn Royal Academy.
Abstract (Originalsprache)
Rabies is a fatal zoonosis caused by the rabies virus (RABV) that has afflicted humans for thousands of years. RABV infection leads to neurological symptoms and death; however, its pathogenesis in the brain is unclear, which complicates patient care. Given that no treatment exists for symptomatic cases, there is an urgent need for effective antiviral drugs. In this study, we aimed to investigate the pathogenic mechanism of RABV in the brain and screen for potential anti-RABV drugs. Protein samples were extracted from the brains of RABV-positive and RABV-negative dogs, and proteomic and phosphoproteomic analyses were conducted. The results showed that the synaptic vesicle cycle is critical to RABV pathogenesis. The kinases involved in the phosphorylation of proteins in the synaptic vesicle cycle were identified and examined as potential drug targets. Casein kinase 2 and protein kinase C were found to be key kinases for RABV replication, and five inhibitors of these enzymes were tested for their anti-RABV properties. Pretreating cells with the kinase inhibitor sunitinib significantly reduced the viral yield after RABV infection. Our findings suggest that RABV interferes with synaptic communication, which leads to rabies, and that inhibiting a vital kinase can reduce viral production. Hence, our findings have implications for the development of rabies treatment regimes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princess Srisavangavadhana Faculty of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.
- Research Center on Clinical and System Microbiology (RCSyM), Chulabhorn Royal Academy, Bangkok, Thailand.
- Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.
- Queen Saovabha Memorial Institute, Thai Red Cross Society, WHO Collaborating Center for Research and Training on Rabies Prophylaxis, Bangkok, Thailand.
- Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Peerut Chienwichai, Rojjanaporn Pulmanausahakul, Onrapak Reamtong
Förderung
- Chulabhorn Royal Academy
Zitieren
APA
Chienwichai, P., Ketsuwan, K., Lumlertdacha, B., Fa-Ngoen, C., Supasawat, P., Pulmanausahakul, R., Masrinoul, P., Thiangtrongjit, T., & Reamtong, O. (2025). Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent. PLOS One. https://doi.org/10.1371/journal.pone.0323931
Vancouver
Chienwichai P, Ketsuwan K, Lumlertdacha B, Fa-Ngoen C, Supasawat P, Pulmanausahakul R, et al. Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent. PLOS One. 2025. doi:10.1371/journal.pone.0323931
BibTeX
@article{Chienwichai2025,
author = {Chienwichai, Peerut and Ketsuwan, Kunjimas and Lumlertdacha, Boonlert and Fa-Ngoen, Chanon and Supasawat, Punchaya and Pulmanausahakul, Rojjanaporn and Masrinoul, Promsin and Thiangtrongjit, Tipparat and Reamtong, Onrapak},
title = {Proteomic and phosphoproteomic analysis of rabies pathogenesis in the clinical canine brain and identification of a kinase inhibitor as a potential repurposed antiviral agent},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0323931}
}
EUVIMED